Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Update

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) saw a significant growth in short interest in December. As of December 15th, there was short interest totalling 111,600 shares, a growth of 8.2% from the November 30th total of 103,100 shares. Approximately 0.7% of the shares of the stock are short sold. Based on an average daily volume of 118,500 shares, the short-interest ratio is currently 0.9 days.

Hedge Funds Weigh In On Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. Sphera Funds Management LTD. purchased a new stake in Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned about 8.46% of Chemomab Therapeutics at the end of the most recent reporting period. Institutional investors own 46.05% of the company’s stock.

Chemomab Therapeutics Stock Performance

Shares of CMMB stock opened at $1.81 on Thursday. The firm’s 50 day moving average price is $1.65 and its two-hundred day moving average price is $1.46. The stock has a market cap of $25.99 million, a PE ratio of -1.81 and a beta of 0.66. Chemomab Therapeutics has a 52-week low of $0.46 and a 52-week high of $2.55.

Wall Street Analyst Weigh In

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $11.00 price objective (down previously from $13.00) on shares of Chemomab Therapeutics in a report on Friday, November 15th.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).